Down 9% on Nov 9 while the S&P 500 rose 2%.
Up 60% over the year to Nov 9 while the S&P 500 rose 12%; down 9% on Nov 9.
4 reasons, from its filings, with the timeline, for Pro members.
DTIL's Quality Score fell 1 point on Tue, Nov 10, to 1. It did not trade higher than the day before.
Follow DTIL's trial news. Pro members can get an alert when Precision BioSciences files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its Nov 2021 high | Down 97% |
| Latest filing | 8-K, Nov 6 |
After its last 4 reports it closed +2.3% on average, higher 2 of 4 times.
The company says its cash lasts into the fourth quarter of 2029 (8-K, Nov 9).
Director Stanley Frankel bought 1,000 shares on Sep 28. 10 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
DTIL is #120 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 120 |
Expected to report Thu Mar 11, before the open (in 121 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.28 a share, from $1.84.
“This decrease in net loss compared to the prior period is primarily driven by the non-cash gain from the warrant liability and does not affect operations or cash runway.”
DTIL's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase of $13.9 million was primarily due to non-cash fair value adjustments, including the gain on change in fair value of the warrant liability.”
From its results filing (SEC filing · Nov 3)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | 0.0% | +0.3% | +39.3% |
| Aug 6, 2026 | -6.3% | -0.7% | -0.7% |
| May 5, 2026 | -7.3% | -2.4% | +3.0% |
Sales grew in five of the last seven years, to $34.3M in 2025. It lost money in 2025 after a profit in 2024.
RSI 66.9, MACD above signal, above both averages. Not scored.
3 insiders bought $30K across 3 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: DTIL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
“As a diversified life sciences company, we compete in multiple different fields.”
DTIL scores 1 today, which Breakaway calls Below Average. It is #120 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 9% on Nov 9 while the S&P 500 rose 2%. Shares: 2.3 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
DTIL scores 1 today, which Breakaway calls Below Average (0 to 5). That is #120 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DTIL's 1.
3 insiders bought $30K across 3 filings in the last 6 months. No open-market sales on record. The newest is Stanley Frankel, Director, who bought $6K on Sep 28. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.